Table 2. Altered phospholipids in subjects with Alzheimer's disease (AD).

Ref. No.	Study design	Sample type	Altered phospholipids
[41]	Healthy control (n = 73), amnestic MCI/AD (n = 46), and converter (n = 28) aged 70 yr and older	Plasma	LysoPC a C18:2, PC aa C36:6, PC aa C38:0, PC aa C38:6, PC aa C40:1, PC aa C40:2, PC aa C40:6, and PC ae C40:6 were depleted in the plasma of the converter subjects
[43]	Healthy control (n = 46), MCI (n = 143), and AD (n = 47)	Serum	PC (18:0/20:4), PC (16:0/18:2), and PC (O-18:0/18:2) were decreased in AD
[44]	Healthy control (n = 17) and AD (n = 19)	Serum	PC (16:1/16:1), PC (16:1/16:0), PC (16:0/16:0), PC (16:1/18:3), PC (16:0/18:3), PC (16:0/18:2), PC (16:0/18:1), PC (16:0/18:0), PC (18:2/18:2), PC (18:2/18:1), PC (18:1/18:1), and PC (18:0/18:0) were increased in AD, while PC (16:0/20:5), PC (18:2/20:5), PC (16:0/22:6), PC (16:0/22:5), PC (18:1/20:4), PC (18:1/20:3), PC (18:0/20:3), and PC (18:0/22:6) were decreased in AD

MCI, mild cognitive impairment; PC, phosphatidylcholine; PC aa, diacyl form; PC ae, acyl-alkyl form.